Scholar Rock Holding Corporation announced the pricing of an upsized underwritten public offering, aiming to raise approximately $300 million in gross proceeds. The offering includes 10,265,488 shares of its common stock priced at $28.25 per share, and pre-funded warrants to purchase 353,983 shares of common stock at $28.2499 per warrant.
The company has also granted the underwriters a 30-day option to purchase up to an additional 1,592,920 shares of common stock at the public offering price. This financing is intended to support the commercialization of apitegromab, advance ongoing and future clinical programs, and further develop its technology platform.
The offering is expected to close on October 10, 2024, subject to customary closing conditions. The capital raised will be vital for Scholar Rock's transition to a commercial-stage biopharmaceutical company and the continued advancement of its pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.